[{"address1": "3963 Maple Avenue", "address2": "Suite 350", "city": "Dallas", "state": "TX", "zip": "75219", "country": "United States", "phone": "972 499 3350", "website": "https://instilbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Mr. Bronson  Crouch", "age": 50, "title": "Chairman & CEO", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 1140189, "exercisedValue": 0, "unexercisedValue": 35349}, {"maxAge": 1, "name": "Dr. Sandeep  Laumas M.D.", "age": 54, "title": "CFO & Chief Business Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 741521, "exercisedValue": 0, "unexercisedValue": 61910}, {"maxAge": 1, "name": "Dr. Mark E. Dudley Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.7, "open": 12.01, "dayLow": 12.0, "dayHigh": 13.24, "regularMarketPreviousClose": 9.7, "regularMarketOpen": 12.01, "regularMarketDayLow": 12.0, "regularMarketDayHigh": 13.24, "beta": 1.185, "forwardPE": -0.87123287, "volume": 461485, "regularMarketVolume": 461485, "averageVolume": 15912, "averageVolume10days": 49820, "averageDailyVolume10Day": 49820, "marketCap": 82729736, "fiftyTwoWeekLow": 6.08, "fiftyTwoWeekHigh": 13.24, "fiftyDayAverage": 10.76242, "twoHundredDayAverage": 9.656175, "currency": "USD", "enterpriseValue": 13942773, "floatShares": 3055929, "sharesOutstanding": 6503910, "sharesShort": 7608, "sharesShortPriorMonth": 6169, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0011999999, "heldPercentInsiders": 0.06842, "heldPercentInstitutions": 0.65366, "shortRatio": 1.0, "shortPercentOfFloat": 0.0044, "bookValue": 31.647, "priceToBook": 0.40193385, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -123321000, "trailingEps": -18.97, "forwardEps": -14.6, "enterpriseToEbitda": -0.193, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TIL", "underlyingSymbol": "TIL", "shortName": "Instil Bio, Inc.", "longName": "Instil Bio, Inc.", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f6e98ce3-ca96-34e6-a1c6-796bed2d60df", "gmtOffSetMilliseconds": -14400000, "currentPrice": 12.72, "targetHighPrice": 32.0, "targetLowPrice": 11.0, "targetMeanPrice": 20.33, "targetMedianPrice": 18.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 154596992, "totalCashPerShare": 23.77, "ebitda": -72356000, "totalDebt": 85810000, "quickRatio": 13.62, "currentRatio": 14.187, "debtToEquity": 41.69, "returnOnAssets": -0.13008, "returnOnEquity": -0.47708, "freeCashflow": -46301876, "operatingCashflow": -61759000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-14"}]